Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Spearheading discussions with NICE, bluebird bio’s UK general manager Nicola Redfern has been central to efforts to introduce fresh reimbursement models within the health technology assessment process and commercial framework. Success could change the way cell and gene therapies are assessed and affect the outlook for many patients living with rare diseases.
Latest From Market Access
Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?
Last month a drug for the prevention of uterine haemorrhage became the first product to be approved under a novel scheme designed to speed up access to medicines in low and middle-income countries, particularly those in sub-Saharan Africa.
In the next evolution of health care, the pharmaceutical industry needs to preserve its customers, not the direct to customer advertising campaigns.
Tony Humphreys of the European Medicines Agency explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost, and why the need to tackle health threats ranked so low in a stakeholder consultation.
Evan Loh, CEO of infectious disease drug developer Paratek Pharmaceuticals, explains why eliminating the DISARM ACT, which focused on finding solutions against antimicrobial resistance, from the new coronavirus aid package is a shortsighted move by US congress.
In Belgium, there are increasing tensions between drug price transparency and getting the best deal for the Belgian government.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.